Protein Sciences’ Flublok won the Food and Drug Administration’s approval in January thus introducing the world to the first recombinant trivalent hemagglutinin (rHA) influenza vaccine, based on a baculovirus expression system. This expression technology is fast becoming the killer app when it comes to producing vaccines efficiently and cost effectively. Genetic Engineering @ Biotechnology News correspondent Lina Genovesi highlights its successes in her report on the baculovirus expression technology track at the ISBiotech conference recently held in Arlington, Va.Read the full story here